Seven months after a building fire closed their pizza pie restaurant, the owners of Pizzeria Toro at Five Points in downtown Durham are bringing it back.
Pizzeria Toro is expected to reopen in late July at its original spot at 105 E. Chapel Hill St. in Durham, says co-owner Jay Owens.
His partners, Gray Brooks and Cara Stacy, will also be back to man the back of the house.
Brooks says the restaurant will have a new ventilation system, but it will also still have the Tuscan-influenced décor in…
After Steve Zelnak retired from his 27-year position as CEO of Martin Marietta Materials, Inc. (NYSE: MLM), a Raleigh-based producer of sand, gravel and crushed rock used in construction, he formed a family enterprise.
Two years ago, Zelnak and his son Brent used their partnership, ZP Enterprises LLC, formed in 2008, to purchase a majority stake in four companies: Accu Tool in Apex, Advanced Machining in Salisbury, Quality Products in Charlotte and Plasma Processes in Huntsville, Alabama.
In a…
Raleigh’s flagship wedding app, WedPics, is kicking into high gear, announcing a slew of partnerships aimed at driving adoption.
The app, which aims to make photo-sharing easier for the whole bridal party, launched partnerships with David’s Bridal, Shutterfly and Wedding Paper Divas this month.
According to founder Justin Miller, the David’s Bridal partnership taps WedPics as the dress chain’s “Preferred Wedding Photo App.” While there’s no financial element fueling the deal, the…
New Jersey company Cancer Genetics Inc. (CGI) announced Monday that it had signed a letter of intent to acquire Morrisville-based Gentris Corp. for $4.75 million.
CGI (Nasdaq: CGIX) plans to pay $3.25 million in cash and $1.5 million in CGI stock plus performance-based earnouts of up to $1.5 million for the company. The transaction will be treated as an asset purchase.
Existing employees at the Morrisville lab should not see their jobs change, but the size of the facility’s staff will likely…
BioCryst’s antiviral candidate got a federal boost today.
The Durham-based company, which is developing an antiviral dubbed BCX4430, had already partnered with the National Institute of Allergy and Infectious Diseases, receiving an initial award of $5 million last September. As part of an amended agreement – the NIAID released an additional $1.89 million for the drug’s development. Specifically, the NIAID has teamed up with BioCryst to develop an IV formulation of the drug.
If all contract…